Corcept TherapeuticsCORT
CORT
About: Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
Employees: 352
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
91% more first-time investments, than exits
New positions opened: 63 | Existing positions closed: 33
63% more call options, than puts
Call options by funds: $54.3M | Put options by funds: $33.3M
40% more funds holding in top 10
Funds holding in top 10: 5 [Q2] → 7 (+2) [Q3]
37% more capital invested
Capital invested by funds: $2.94B [Q2] → $4.03B (+$1.09B) [Q3]
11% more funds holding
Funds holding: 284 [Q2] → 314 (+30) [Q3]
1% more repeat investments, than reductions
Existing positions increased: 104 | Existing positions reduced: 103
3.62% less ownership
Funds ownership: 87.0% [Q2] → 83.38% (-3.62%) [Q3]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$76
48%
upside
Avg. target
$78
52%
upside
High target
$80
56%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Swayampakula Ramakanth 30% 1-year accuracy 52 / 173 met price target | 56%upside $80 | Buy Reiterated | 31 Oct 2024 |
Truist Securities Joon Lee 47% 1-year accuracy 17 / 36 met price target | 48%upside $76 | Buy Maintained | 30 Sept 2024 |
Financial journalist opinion
Based on 12 articles about CORT published over the past 30 days
Neutral
Business Wire
6 days ago
Corcept's Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, presented results from its Phase 3 long-term, open-label extension study of relacorilant to treat patients with endogenous hypercortisolism (Cushing's syndrome) at the WCIRDC. The results from this.
Neutral
Business Wire
1 week ago
Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing's Syndrome) and Difficult-to-Control Diabetes
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the primary endpoint was met in the treatment phase of CATALYST, a randomized, double-blind, placebo-controlled study of Korlym® in patients with hypercortisolism (Cushing's syn.
Positive
Zacks Investment Research
1 week ago
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder Study
The phase II DAZALS study evaluating Corcept's dazucorilant in patients with amyotrophic lateral sclerosis fails to meet the primary goal.
Negative
Reuters
1 week ago
Corcept Therapeutics' ALS drug fails in mid-stage trial
Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients with amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease.
Neutral
Business Wire
1 week ago
Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol, today announced results from the DAZALS study, a randomized, double-blind, placebo-controlled, Phase 2 trial evaluating two doses (150 mg and 300 mg) of its proprietary selective cortisol modulator.
Positive
Zacks Investment Research
1 week ago
Here's Why Corcept Therapeutics (CORT) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Positive
Zacks Investment Research
1 week ago
Corcept (CORT) is an Incredible Growth Stock: 3 Reasons Why
Corcept (CORT) could produce exceptional returns because of its solid growth attributes.
Positive
Zacks Investment Research
2 weeks ago
Wall Street Analysts See a 26.05% Upside in Corcept (CORT): Can the Stock Really Move This High?
The consensus price target hints at a 26.1% upside potential for Corcept (CORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Positive
Zacks Investment Research
2 weeks ago
What Makes Corcept (CORT) a Good Fit for 'Trend Investing'
Corcept (CORT) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Positive
Zacks Investment Research
3 weeks ago
Corcept (CORT) Up 19.7% Since Last Earnings Report: Can It Continue?
Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
Charts implemented using Lightweight Charts™